NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

Thomas A. Hope; Lisa Bodei; Jennifer A. Chan; Ghassan El-Haddad; Nicholas Fidelman; Pamela L. Kunz; Josh Mailman; Yusuf Menda; David C. Metz; Erik S. Mittra; Daniel A. Pryma; Diane L. Reidy-Lagunes; Simron Singh; Jonathan R. Strosberg

doi:10.2967/jnumed.119.240911

Article Figures & Data

Tables

View popup

TABLE 1

Experience with PRRT by Site of Primary Tumor

Author	Year	Patients^*	Treatment	ORR	PFS	OS
Midgut NETs (grade 9)
Strosberg (7)	2017	116	¹⁷⁷Lu-DOTATATE	18%, 18/101	NR	NR
Sabet (3)	2015	61	¹⁷⁷Lu-DOTATATE	13%, 8/61	33	61
Hörsch (5)	2016	138	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	NR	51	NR
Brabander (4)	2017	181	¹⁷⁷Lu-DOTATATE	31%, 57/181	30	60
Baum (6)	2018	315	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	NR	22	69
Pancreatic NETs (grade 8)
Baum (6)	2018	315	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	NR	20	44
Hörsch (5)	2016	172	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	NR	39	53
Brabander (4)	2017	133	¹⁷⁷Lu-DOTATATE	55%, 72/133	30	71
Ezziddin (10)	2014	68	¹⁷⁷Lu-DOTATATE	60%, 41/68	34	53
Sansovini (53)	2017	60	¹⁷⁷Lu-DOTATATE	30%, 18/60	29	NR
Garske-Román (9)	2018	48	¹⁷⁷Lu-DOTATATE	45%, 22/49	NR	NR
Bronchial carcinoid (before everolimus grade 6; after everolimus grade 7)
Mariniello (54)	2016	114	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	13%, 15/114	28	59
Baum (6)	2018	75	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	NR	11	40
Ianniello (55)	2017	34	¹⁷⁷Lu-DOTATATE	15%, 4/32	19	49
Brabander (4)	2017	23	¹⁷⁷Lu-DOTATATE	30%, 7/23	20	52
Parghane (56)	2017	22	¹⁷⁷Lu-DOTATATE	11%, 2/19	NR	40
Sabet (57)	2017	22	¹⁷⁷Lu-DOTATATE	27%, 6/22	27	42
Unknown primary tumor (grade 8)
Baum (6)	2018	151	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	NR	13	53
Brabander (4)	2017	82	¹⁷⁷Lu-DOTATATE	35% 29/82	29	53
Delpassand (58)	2014	7	¹⁷⁷Lu-DOTATATE	NR	11	NR
Bodei (11)	2011	3	¹⁷⁷Lu-DOTATATE	0% 0/3	NR	NR
Paraganglioma/pheochromocytoma (MIBG positive grade 5; MIBG negative grade 7)
Forrer (17)	2008	28	¹⁷⁷Lu-DOTATATE ⁹⁰Y-DOTATOC	7%, 2/28	NR	NR
Kong (18)	2017	20	¹⁷⁷Lu-DOTATATE	29%, 5/17	39	NR
van Essen (16)	2006	12	¹⁷⁷Lu-DOTATATE	17%, 2/12	NR	NR

↵* Only within NET subtype (n).
ORR = overall response rate; PFS = progression free survival (in months); OS = overall survival (in months); NR = not reported/reached.